Literature DB >> 1659860

CD16 and CR3 receptors distinguish between the two mechanisms of tumour cytotoxicity in neutrophils.

R Gavioli1, S Spisani, A L Giuliani, E Cosulich, A Risso, S Traniello.   

Abstract

Previous studies have suggested that phorbol ester-activated neutrophils kill both antibody non-coated and antibody-coated K562 target cells. In this report the contribution of the receptors Fc gamma III (CD16) and CR3 (CD11b/CD18) in the lytic process was investigated. In neutrophils CD16 and CR3 are up-regulated by the phorbol ester up to 4 and 10 times, respectively. As expected, lysis of non-immunized K562 targets is not affected by the treatment of neutrophils with anti CD16, AB8.28, whereas lysis of immunized targets is decreased by 50%. In addition, the interaction of CD16 and AB8.28 induces calcium mobilization and increases granule secretion. Surprisingly, the simultaneous binding of AB8.28 and anti-CR3 OKM1 to neutrophils completely abolishes the lysis of antibody-coated targets. Unlike CD16, CR3 does not possess a functional role and binding of OKM1 to CR3 does not affect cytotoxicity of immunized K562 targets, but it blocks lysis of non-coated target almost completely, indicating a function as adhesion protein for CR3. These studies demonstrate a distinct role of CD16 and CR3 in mediating antibody-dependent and antibody-independent cellular cytotoxicity, respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659860     DOI: 10.1111/j.1365-2141.1991.tb04518.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity.

Authors:  S Spisani; S Traniello; C Martuccio; O Rizzuti; L Cellai
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

3.  3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions.

Authors:  S Spisani; S Traniello; A M Onori; O Rizzuti; C Martuccio; L Cellai
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

4.  FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils.

Authors:  L Ottonello; P Morone; M Mancini; M Amelotti; P Dapino; F Dallegri
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc gamma -receptors.

Authors:  L Ottonello; A L Epstein; M Mancini; G Tortolina; P Dapino; F Dallegri
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.